The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Standard counseling for the choice of hormonal contraceptive for safe long-term use (literature review)

Journal: Russian Journal of Human Reproduction. 2020;26(2): 87‑94

DOI: 10.17116/repro20202602187

Read: 3024 times

Download PDF (RU)
Contact the author
Table of contents

STANDARD COUNSELING FOR THE CHOICE OF HORMONAL CONTRACEPTIVE FOR SAFE LONG-TERM USE (LITERATURE REVIEW)
STANDARD COUNSELING FOR THE CHOICE OF HORMONAL CONTRACEPTIVE FOR SAFE LONG-TERM USE (LITERATURE REVIEW)

To cite this article:

Standard counseling for the choice of hormonal contraceptive for safe long-term use (literature review). Russian Journal of Human Reproduction. 2020;26(2):87‑94. (In Russ.)
https://doi.org/10.17116/repro20202602187

Подписка 2026 Проблемы репродукции (Russian Journal of Human Reproduction)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Endo­metriosis-associated infe­rtility and the effi­cacy of dienogest. Russian Journal of Human Reproduction. 2025;(5):58-63
Expe­rience of using ribo­ciclib in the therapy of meta­static breast cancer in a regional onco­logical dispensary. P.A. Herzen Journal of Onco­logy. 2025;(3):89-93
Resu­lts of the inte­rnational multicenter randomized, double-blind, placebo-controlled clinical trial for the evaluation of the effi­cacy and safety of the sequential therapy with ethy­lmethylhydroxypyridine succinate in patients in the acute and early reco­very periods of ischemic stroke (MIR). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8-2):40-53
Resu­lts of an open-label, randomized, multicenter, comparative study of clinical effi­cacy and safety of Pulmibud drug and Pulmicort drug in patients with partially controlled and unco­ntrolled persistent bronchial asthma. Journal of Respiratory Medi­cine. 2025;(3):33-38
Asso­ciations of poly­morphic variants of CYP2C19*2, *17 with effe­ctiveness and safety of sertraline in adolescents with a depressive episode and suicidal tendencies. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10-2):12-20
Onasemnogene abeparvovec gene replacement therapy for spinal muscular atro­phy in children: a Moscow expe­rience. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10-2):103-113
Spectrum of tole­rability and safety of the use of brain—computer inte­rfaces with biofeedback in cognitive reha­bilitation after a stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(12-2):86-93
An open-label obse­rvational study of the effi­cacy and tole­rability of rapi­dly dissolving forms of aceclofenac and nime­sulide for oral use in the treatment of patients with acute non-specific low back pain (ASTRA study). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(12):141-147
Effi­cacy and safety of Cortexin as addi­tional therapy in patients with depressive diso­rder. S.S. Korsakov Journal of Neurology and Psychiatry. 2026;(2):92-96
Abstract:

We performed a systematic review of literature data, published in Pubmed over the past 20 years, on the main aspects of the effectiveness and safety of hormonal contraceptive containing estradiol valerate with dienogest with 26+2 regimen. Summarizing the literature, it should be noted that combination of estradiol valerate with a dienogest with 26+2 regimen has higher contraceptive effectiveness and better cycle control, lower frequency of hormone withdrawal-associated symptoms, better tolerance and safety profile compared to standard ethinyl estradiol-containing COCs.

Keywords:

contraception
estradiol valerate
dienogest
hormone withdrawal-associated symptoms
safety

Close metadata

References:

  1. MacGregor EA, Guillebaud J. The 7-day contraceptive hormone-free interval should be consigned to history. . 2018;44:214-220. 
  2. Trussell J, Aiken ARA, Guthrie KA. Efficacy, safety and personal considerations. In: Hatcher RA, Nelson AL, Trussel J, Cwiak C, Cason P, Policar MS, Edelman A, Aiken ARA, Marrazzo J, Kowal D, eds. . 21 ed. New York, NY: Ayer Conpany Publishers, Inc.; 2018.
  3. WHO Family planning and contraception. Available at: Accessed March 03, 2020.
  4. Trussell J. Contraceptive failure in the United States. 2011;83(5):397-404. 
  5. Palacios S, Wildt L, Parke S, Machlitt A, Römer T, Bitzer J. Efficacy and safety of a novel oral contraceptive based on oestradiol (oestradiol valerate/dienogest): A phase III trial. 2010;149(1):57-62.
  6. Barnett С, Hagemann С, Dinger J, Minh TD, Heinemann K. Fertility and combined oral contraceptives — unintended pregnancies and planned pregnancies following oral contraceptive use — results from the INAS-SCORE study. . 2017;22(1):17-23. 
  7. Graziottin A. The shorter, the better: a review of the evidence for a shorter contraceptive hormone-free interval. 2016;21:93-105. 
  8. Dinger JC, Minh TD, Buttmann N, Bardenheuer K. Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen. . 2011;117(1):33-40. 
  9. Davis AR, Kroll R, Soltes B, Zhang N, Grubb GS, Constantine GD. Occurrence of menses or pregnancy after cessation of a continuous oral contraceptive. 2008;89(5):1059-1063.
  10. Jacobs HS, Knuth UA, Hull MG, Franks S. Post-«pill» amenorrhoea — cause or coincidence? 1977; 2(6092):940-942.
  11. Ahrendt HJ, Makalová D, Parke S, Mellinger U, Mansour D. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel 2009;80(5):436-444. 
  12. Briggs P, Serrani M, Vogtländer K, Parke S. Continuation rates, bleeding profile acceptability, and satisfaction of women using an oral contraceptive pill containing estradiol valerate and dienogest versus a progestogen-only pill after switching from an ethinylestradiol-containing pill in a real-life setting: results of the CONTENT study. 2016;8:477-487. 
  13. Fraser IS, Römer T, Parke S, Zeun S, Mellinger U, Machlitt A, Jensen JT. Effective treatment of heavy and/or prolonged menstrual bleeding with an oral contraceptive containing estradiol valerate and dienogest: A randomized, double-blind Phase III trial. . 2011;26(10):2698-2708.
  14. Jensen JT, Parke S, Mellinger U, Machlitt A, Fraser IS. Effective treatment of heavy menstrual bleeding with estradiol valerate and dienogest: A randomized controlled trial. . 2011;117(4):777-787. 
  15. Fraser IS, Parke S, Mellinger U, Machlitt A, Serrani M, Jensen J. Effective treatment of heavy and/or prolonged menstrual bleeding without organic cause: Pooled analysis of two multinational, randomised, double-blind, placebo-controlled trials of oestradiol valerate and dienogest. 2011;16(4):258-269. 
  16. Shabaan MM, Zakherah MS, El-Nashar SA, Sayed GH. Levonorgestrel-releasing intrauterine system compared to low dose combined oral contraceptive pills for idiopathic menorrhagia: A randomized clinical trial. 2011;83(1):48-54. 
  17. Thomas SL, Ellertson C. Nuisance or natural and healthy: Should monthly menstruation be optional for women? 2000; 355(9207):922-924. 
  18. Pincus G, Rock J, Garcia CR, Ricewray E, Paniagua M, Rodriguez I. Fertility control with oral medication. 1958;75(6):1333-1346.
  19. Nappi RE, Terreno E, Sances G, Martini E, Tonani S, Santamaria V, Tassorelli C, Spinillo A. Effect of a contraceptive pill containing estradiol valerate and dienogest (E 2 V/DNG) in women with menstrually-related migraine (MRM). Contraception. 2013;88(3): 369-375. 
  20. Jensen JT, Parke S, Mellinger U, Serrani M, Mabey RG Jr. Hormone withdrawal-associated symptoms: comparison of oestradiol valerate/dienogest versus ethinylestradiol/norgestimate. 2013;18:274-283. 
  21. Macìas G, Merki-Feld GS, Parke S, Mellinger U, Serrani M. Effects of a combined oral contraceptive containing oestradiol valerate/dienogest on hormone withdrawal-associated symptoms: Results from the multicentre, randomised, double-blind, activecontrolled HARMONY II study. 2013;33(6):591-596. 
  22. Davis SR, Bitzer J, Giraldi A, Palacios S, Parke S, Serrani M, Mellinger U, Nappi RE. Change to Either a Nonandrogenic or Androgenic Progestin-Containing Oral Contraceptive Preparation is Associated with Improved Sexual Function in Women with Oral Contraceptive-Associated Sexual Dysfunction. . 2013;10(12):3069-3079.
  23. Caruso S, Agnello C, Romano M, Cianci S, Lo Presti L, Malandrino C, Cianci A. Preliminary study on the effect of four-phasic estradiol valerate and dienogest (E2V/DNG) oral contraceptive on the quality of sexual life. . 2011;8(10):2841-2850.
  24. Petraglia F, Parke S, Serrani M, Mellinger U, Römer T. Estradiol valerate plus dienogest versus ethinylestradiol plus levonorgestrel for the treatment of primary dysmenorrheal. . 2014;125(3):270-274. 
  25. Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: A prospective evaluation of frequency and reasons. . 1998;179(3 Pt 1):577-582. 
  26. Sitruk-Ware R, Nath A. Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills. 2013; 27:13-24. 
  27. Klipping C, Duijkers I, Parke S, Mellinger U, Serrani M, Junge W. Hemostatic effects of a novel estradiol-based oral contraceptive: an open-label, randomized, crossover study of estradiol valerate/dienogest versus ethinylestradiol/levonorgestrel. 2011;11(2):159-170. 
  28. Junge W, Mellinger U, Parke S, Serrani M. Metabolic and Haemostatic Effects of Estradiol Valerate/Dienogest, a Novel Oral Contraceptive a Randomized, Open-Label, Single-Centre Study. 2011;31(8):573-584. 
  29. Strowitzki T, Faustmann T, Gerlinger C, Seitz C. Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study. 2010;151(2): 193-198. 
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.